Insmed

Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. The company was founded in 1988 and is headquartered in Bridgewater, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Insmed reports robust earnings, eyes pipeline expansion and regulatory support

Insmed's strong financial performance in 2022, driven by ARIKAYCE revenue and prudent cost management, sets a solid foundation for future growth. The company's focus on pipeline expansion, regulatory enthusiasm for brensocatib, and strategic milestones position it well for success. Challenges in the NTM market and pandemic-related impacts require careful navigation, but opportunities in new trials and gene therapy offer promising avenues for growth.

Insmed excels in Q1 with revenue growth and trial milestones

Insmed's strong Q1 performance driven by revenue growth and successful trial enrollments.
Challenges include regulatory differences and unblinding requirements for trial outcomes.
Opportunities lie in expanding ARIKAYCE's market reach and showcasing research efforts.
Financial stability and positive program reviews position Insmed well for future growth.

Insmed achieves record sales, strengthens capabilities in untreatable diseases

Insmed's Q2 2023 performance reflects robust sales growth, improved financial stability, and strategic acquisitions, positioning the company for future success.
The company's strengths lie in its commercial performance, innovative treatment formulations, and enhanced capabilities in synthetic rescue for untreatable diseases.
While facing challenges in clinical trial success and financial management, Insmed has opportunities to leverage its R&D portfolio, expedite drug approvals, and drive growth in key therapeutic areas.

Insmed reports record revenues and advances in trials, poised for growth

Insmed's Q3 2023 performance reflects record revenues for ARIKAYCE and positive trial results for brensocatib, positioning the company for continued growth.
Strong cash reserves, successful commercial activities, and promising trial data highlight Insmed's strengths and potential for future success in the biopharmaceutical market.
While facing funding challenges and trial complexities, Insmed has opportunities to leverage trial outcomes, enhance treatment efficacy, and secure financing for growth.
Overall, Insmed's strategic focus on product performance, financial stability, and innovation underscores its commitment to advancing therapies and driving shareholder value.

Insmed reports strong earnings, projects brensocatib sales exceeding $5B

Insmed's Q4 2023 earnings call highlighted strong financial performance, positive trial results, and strategic initiatives to maintain cash balance and drive commercial opportunities
The company's focus on patient-centric approaches, diverse early-stage assets, and opportunities for label expansion and commercial success position Insmed for future growth
While facing challenges related to placebo effects, regulatory requirements, and therapeutic advancements, Insmed's emphasis on reducing exacerbation rates and pursuing innovative therapies presents avenues for overcoming obstacles
With a robust cash position, promising pipeline developments, and a clear commercial outlook, Insmed demonstrates resilience and potential for market impact in the biopharmaceutical industry

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Insmed, Inc. (INSM) CEO William Lewis on Q1 2019 Results - Earnings Call Transcript

News for Insmed Stock (INSM)